Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aptose Biosciences ( (TSE:APS) ) has provided an update.
On May 27, 2025, Aptose Biosciences held its Annual and Special Meeting of shareholders, where all proposed resolutions were approved. Key outcomes included the re-election of directors, approval of executive compensation, amendments to the stock incentive plan, and authorization for a reverse stock split. The meeting was adjourned to finalize the appointment of a new auditor, with further details to be announced.
The most recent analyst rating on (TSE:APS) stock is a Buy with a C$210.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology. The company is advancing a pipeline of small molecule cancer therapeutics, including its lead compound tuspetinib (TUS), an oral kinase inhibitor for acute myeloid leukemia (AML).
Average Trading Volume: 5,509
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$6.13M
Find detailed analytics on APS stock on TipRanks’ Stock Analysis page.